Search clinical trials for: patients with mCRC who failed 2nd therapy or more

Total 324735 results

Hutchison Medipharma Limited
Sun Yat-sen University; Fudan University

Completed

A Phase Ib Study of Fruquintinib in 3rd Line mCRC

Colorectal Cancer

China
Boehringer Ingelheim

Completed

Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)

Leukemia, Myeloid, Acute

Korea, Republic of, Spain, Canada, Germany, Norway, Taiwan, Belgium, United States, Japan, Mexico, France, Greece, Italy, India, Austria, Portugal, Czechia, Russian Federation, Hungary, Brazil, Argentina, Finland, Netherlands, Poland, South...
Ractigen Therapeutics.

Recruiting

A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

Non-Muscle-Invasive Bladder Cancer (NMIBC)

Australia
Institute of Hematology & Blood Diseases Hospital...
Suzhou Fundamenta Therapeutics

Recruiting

CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy

Autoimmune Hemolytic Anemia | CD19 CAR-T Cell Infusion

China
Soonchunhyang University Hospital

Not yet recruiting

A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy (DICI_PC)

Pancreas Cancer
Wuhan Union Hospital, China
Guangzhou Bio-gene Technology Co., Ltd

Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy

Multiple Myeloma

China
UNICANCER
Novartis; Breast Cancer Research Foundation

Recruiting

Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib (SAFIR 03)

Breast Cancer Stage IV

France
National Cancer Institute (NCI)

Recruiting

M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma

Colorectal Neoplasms | Colorectal Cancer | Cholangiocarcinoma | Bile Duct Cancer | Bile Duct Neoplasms | Metastatic Colorectal Cancer (Mcrc) | Intrahepatic Cholangiocarcinoma (Icc) | Intrahepatic Bile Duct Cancer

United States
Chong Kun Dang Pharmaceutical
Samsung Medical Center; Asan Medical Center; Seoul National University Hospital

Recruiting

The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy (CKD-702)

Non-Small Cell Lung Cancer

Korea, Republic of
Hoffmann-La Roche

Recruiting

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011)

Muscle-invasive Bladder Cancer

Belgium, Korea, Republic of, Japan, Brazil, China, United States, Singapore, France, United Kingdom, Canada, Greece, Italy, Spain, Turkey, Russian Federation, Ukraine, Israel, Czechia, Colombia, Hong Kong, Argentina, Germany, Ireland, Polan... and more
Pfizer
Arena is a wholly owned subsidiary of Pfizer

Recruiting

A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease (CULTIVATE)

Crohn's Disease

United States, Korea, Republic of, Netherlands, Colombia, Israel, Italy, Lebanon, Mexico, Poland, Spain, Turkey, Australia, Georgia, Czechia, Belgium, Germany, South Africa, Greece, Russian Federation, United Kingdom, Croatia, Serbia and more
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Active, not recruiting

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States, Canada, Israel, Hong Kong, Singapore, Switzerland
SYZ Cell Therapy Co..

Completed

MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy.

Solid Tumors

China
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Active, not recruiting

Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

Breast Cancer

United States, Canada, Israel, Hong Kong, Korea, Republic of, Singapore, Switzerland, Japan
Cellectar Biosciences, Inc.

Completed

A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy (NOV-205)

Hepatitis C

United States
Sanofi
Hanmi Pharmaceutical Company Limited

Terminated

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea (AMPLITUDE-S)

Type 2 Diabetes Mellitus

United States, China, Taiwan
Novartis Pharmaceuticals

Completed

A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab

Metastatic Breast Cancer (MBC) | Locally Advance Breast Cancer (LABC)

United Kingdom, Spain
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases

Iris Melanoma | Medium/Large Size Posterior Uveal Melanoma | Stage IIA Uveal Melanoma | Stage IIB Uveal Melanoma | Stage IIIA Uveal Melanoma | Stage IIIB Uveal Melanoma | Stage IIIC Uveal Melanoma

United States
Eastern Regional Medical Center

Available

Domperidone Expanded Access Program for Oncology Patients With Gastroparesis Who Have Failed Standard Therapy

Oncology Patients With Gastroparesis

United States
Lexicon Pharmaceuticals
Sanofi

Completed

A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone (inTandem3)

Type 1 Diabetes Mellitus (T1DM) | High Level of Sugar (Glucose) in the Blood

United States, Australia, Spain, Belgium, Argentina, Bulgaria, Canada, Colombia, Czechia, France, Germany, Hungary, Israel, Italy, New Zealand, Poland, Slovakia, South Africa, United Kingdom
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy (inTandem1)

Type 1 Diabetes Mellitus

United States, Canada
Roswell Park Cancer Institute
Iovance Biotherapeutics, Inc.

Withdrawn

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial Carcinoma

United States
Clovis Oncology, Inc.

Terminated

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Non-small Cell Lung Cancer

Korea, Republic of, United States, France, Germany, Netherlands, Australia, Spain, Taiwan, United Kingdom, Italy
Yonsei University

Unknown

An Open Label, Single Arm, Multicenter Phase II Study of BYL719 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy.

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Korea, Republic of
Medical University of South Carolina
Bristol-Myers Squibb

Withdrawn

Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab

Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma

United States
AstraZeneca

Completed

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Type 2 Diabetes

United States, Hungary, Mexico, South Africa, Romania, Poland
Seoul National University Hospital

Unknown

A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy

Head and Neck Neoplasms | HNSCC

Korea, Republic of
University of Miami

Completed

Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy

Pancreatic Cancer

United States, Singapore
University of California, San Francisco
North American Gamma Knife Consortium

Withdrawn

Neurocognitive Outcomes In Patients Treated With Radiotherapy For Five Or More Brain Metastases (NAGKC 12-01)

Brain Metastases

United States
ANRS, Emerging Infectious Diseases
Bristol-Myers Squibb

Completed

Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)

Hepatitis C Virus Genotype 4 Infection

France
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Crohn's Disease | Colitis | Inflammatory Bowel Disease | IBD

United States, France, Poland, United Kingdom, Germany, Spain, Serbia, South Africa, Japan, Israel, Canada, Australia, Netherlands, Korea, Republic of, Belgium, New Zealand, Brazil, Austria, Ireland, Czech Republic, Hungary, Denmark, Icela...
Genzyme, a Sanofi Company

Completed

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE) (ENCORE)

Gaucher Disease, Type 1

United States, France, Germany, Italy, Brazil, Australia, Argentina, Canada, Egypt, Russian Federation, Spain, United Kingdom
Ohio State University Comprehensive Cancer Center
National Comprehensive Cancer Network; Spectrum Pharmaceuticals, Inc

Completed

Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy

Squamous Cell Carcinoma of the Esophagus | Adenocarcinomas of the Gastroesophageal Junction | Adenocarcinoma of the Esophagus | Recurrent Esophageal Cancer | Stage IV Esophageal Cancer

United States
Bristol-Myers Squibb

Completed

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment (HEPCAT)

Hepatitis C Virus

Australia, France, Mexico, United States, Canada, Germany, Denmark, Italy, Puerto Rico, Sweden, Argentina
AstraZeneca

Completed

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

Pancreatic Cancer

United States, Bulgaria, Hungary, Romania, Australia
National Cancer Institute (NCI)

Terminated

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
Pfizer

Completed

Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib (INTORSECT)

Renal Cell Carcinoma

United States, Australia, Canada, Spain, France, Italy, Korea, Republic of, Denmark, Germany, United Kingdom, Singapore, Netherlands, Austria, Sweden, Chile, Argentina, China, Finland, Hungary, Switzerland
Azaya Therapeutics, Inc.

Completed

Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies

Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Solid Tumor | Non-Small Cell Lung

United States
BioCryst Pharmaceuticals

Terminated

Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens

Lymphoma | Leukemia

United States
Bristol-Myers Squibb

Completed

Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.

Rheumatoid Arthritis

United States
Novartis Pharmaceuticals

No longer available

Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy

Metastatic Renal Cell Cancer

United States, United Kingdom, Czech Republic, Canada, Germany, Lebanon, Turkey, Hungary, Norway, Australia, Austria, Belgium, Switzerland
Bristol-Myers Squibb

Completed

Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy

Breast Cancer | Solid Tumor

United States
Bristol-Myers Squibb

Terminated

A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor

HIV Infections

United States, Mexico, Canada, Puerto Rico, Thailand
National Institute of Allergy and Infectious Diseases...
Bristol-Myers Squibb

Completed

A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment

HIV Infections

United States, Puerto Rico
Bader, Ted, M.D.

Completed

Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy

Chronic Hepatitis C

United States
Bristol-Myers Squibb

Terminated

A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy

Leukemia

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Non-Small Cell Lung Cancer

Belgium
Abbott

Completed

An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY) (RHAPSODY)

Ankylosing Spondylitis

France, Germany, Greece, Italy, Switzerland, Spain, United Kingdom, Belgium, Austria, Netherlands, Norway, Denmark, Finland, Ireland, Sweden
OSI Pharmaceuticals

Completed

A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy

Locally Recurrent or Metastatic Cancer of the Head and Neck | Must Have Failed First-Line Therapy

United States
Hepatitis Resource Network
Hoffmann-La Roche

Completed

PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy

Chronic Hepatitis C Virus Infection

United States

3

Subscribe